89720-77-4 Usage
Description
4-BROMO-1-BROMOMETHYL-2-CHLORO-BENZENE is an organic compound characterized by the presence of a benzene ring with a bromine atom at the 4th position, a bromodimethyl group at the 1st position, and a chlorine atom at the 2nd position. This unique structure endows it with specific chemical properties that make it suitable for various applications in different industries.
Uses
Used in Pharmaceutical Industry:
4-BROMO-1-BROMOMETHYL-2-CHLORO-BENZENE is used as a key intermediate in the synthesis of selective aldose reductase inhibitors. These inhibitors are important for the development of drugs that can treat diabetic complications, such as diabetic neuropathy, cataract, and retinopathy, by reducing the activity of aldose reductase, an enzyme involved in sugar metabolism.
Check Digit Verification of cas no
The CAS Registry Mumber 89720-77-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,9,7,2 and 0 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 89720-77:
(7*8)+(6*9)+(5*7)+(4*2)+(3*0)+(2*7)+(1*7)=174
174 % 10 = 4
So 89720-77-4 is a valid CAS Registry Number.
89720-77-4Relevant articles and documents
HISTONE METHYLTRANSFERASE EZH2 INHIBITOR, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF
-
, (2019/11/22)
The invention relates to a histone methyltransferase EZH2 inhibitor, a preparation method and pharmaceutical use thereof. In particular, the invention relates to a compound represented by the general formula (I), a preparation method thereof, a pharmaceut
SERINE/THREONINE KINASE INHIBITORS
-
Paragraph 0341; 0340, (2015/02/19)
Compounds having the formula I wherein R1, R2, R3, R4, R5, Ra, Rb, Rc, Rd, Re, n, r, s and t are as defined herein and which compounds are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.
NEPRILYSIN INHIBITORS
-
, (2015/09/23)
In one aspect, the invention relates to compounds having the formula (I): where R1-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.